Results 61 to 70 of about 116,439 (236)

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon   +8 more
wiley   +1 more source

Dysregulation of U12‐Type Splicing in Lupus Neutrophils

open access: yesArthritis &Rheumatology, Accepted Article.
Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco   +11 more
wiley   +1 more source

Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma

open access: yesActa Medica Iranica, 2016
Melasma is a common acquired skin disorder. While different treatments are currently being used, in many cases it is refractory to treatment. According to the effects of topical steroids in decreasing skin pigmentation, we studied the efficacy of this ...
Gholamreza Eshghi   +2 more
doaj  

Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES

open access: yesFrontiers in Immunology
BackgroundThe systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) are both novel biomarkers and predictors of inflammation. Psoriasis is a skin disease characterized by chronic inflammation.
Rui Ma   +25 more
doaj   +1 more source

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/Fn14 signaling in SLE‐related cardiomyopathy and its potential as a ...
Yale Liu   +12 more
wiley   +1 more source

Viewing Psoriasis as a Systemic Disease for Better Health Outcomes

open access: yesJID Innovations, 2021
George C. Gondo   +4 more
doaj   +1 more source

Epigenetic control of tissue resident memory T cells

open access: yesFrontiers in Immunology
Tissue-resident memory T cells (TRM) represent a heterogeneous population of T cells that exhibit both effector and memory functionalities. They express specific gene signatures that enable them to occupy tissues without recirculating, thus providing a ...
Zhiyi Lan   +14 more
doaj   +1 more source

A New Era for Using Natural Pigments: The Case of the C50 Carotenoid Called Bacterioruberin

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Haloarchaea are extremophilic microorganisms belonging to the Archaea domain that require high salt concentrations to live, thus inhabiting ecosystems like salty ponds, salty marshes, or extremely salty lagoons. They are more abundant and widely distributed worldwide than initially expected.
Micaela Giani   +5 more
wiley   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale   +5 more
wiley   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy